Beijing-based Lepu Medical, maker of the heart attack risk warning system device, at just $2 per day, faces resistance in the US even if it is backed by the largest patient data set.
Lepu's subsidiary, Shenzhen Carewell Electronics, developed the analytics system and incorporated around 47 million pieces of data from over half a million patients in 2,500 Chinese hospitals.
The American Heart Association's data indicate that heart diseases had cost the US $555 billion in 2016.
This amount is expected to double to US$1.1 trillion by 2035 with one death every 40 seconds happening.
Twenty-eight million or 11 percent of adult Americans have heart disease though, in China, the number is higher with around 290 million people estimated to have cardiovascular diseases.
China's state-run medical system is very eager to cut treatment costs using new technology.
A company official said that even if the Food and Drug Administration approved the device, China's largest medical device maker is getting resistance from the US industry players for its artificial intelligence-powered heart attack risk warning system.
David Chung, who heads Maryland-based Carewell Health, a subsidiary of Lepu, said that either health care operators see the heart analytics system device a threat to their income or they want to develop their systems.
Chung added that American doctors get paid during hospital visits and Lepu's technology means people can avoid heart surgeries and save themselves doctor visits, both non-income generators.
The importance of doctors' approval in the US is very important because a famous doctor's endorsement is needed for new products to be marketed.
Doctors have to test the product and write about it in clinical papers for international medical journals.
This process alone could cost a quarter to half a million dollars for just a single product and take a year to 18 months to fully happen, Chung said.
However, a conservative stance towards this new technology by hospital administrators is because it is prone to high litigation risks.
Three years ago, Lepu acquired Shenzhen Carewell Electronics that developed the heart analytics system and from then put in the million pieces of data from over half a million patients in Chinese hospitals.
Lepu says its system can identify 107 heart symptoms 95 percent of the time.
This percentage is higher than the 70 percent rate of accuracy of human doctors who read through heart data.
Lepu's heart analytics device will help doctors at large hospitals reduce their time on such a task.
At the same time, the device will enable smaller clinics or nursing homes without cardiologists to make a quick and accurate analysis of the electrocardiogram, ECG.
By sending alerts before a heart attack strikes, patients can get treated before they need expensive surgeries and become reliant on drugs.
